Shufro Rose & Co. LLC lowered its stake in shares of Medtronic PLC (NYSE:MDT) by 0.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,331 shares of the medical technology company’s stock after selling 50 shares during the period. Shufro Rose & Co. LLC’s holdings in Medtronic PLC were worth $917,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Donaldson Capital Management LLC acquired a new stake in shares of Medtronic PLC during the 2nd quarter valued at $22,813,000. Trillium Asset Management LLC boosted its stake in shares of Medtronic PLC by 2.1% during the 2nd quarter. Trillium Asset Management LLC now owns 184,421 shares of the medical technology company’s stock valued at $16,367,000 after buying an additional 3,761 shares during the period. Pinnacle Financial Partners Inc. boosted its stake in shares of Medtronic PLC by 24.8% during the 2nd quarter. Pinnacle Financial Partners Inc. now owns 44,809 shares of the medical technology company’s stock valued at $3,977,000 after buying an additional 8,894 shares during the period. Alpine Woods Capital Investors LLC boosted its stake in shares of Medtronic PLC by 0.7% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 154,300 shares of the medical technology company’s stock valued at $13,694,000 after buying an additional 1,000 shares during the period. Finally, Advisors Asset Management Inc. boosted its stake in shares of Medtronic PLC by 7.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 262,450 shares of the medical technology company’s stock valued at $23,292,000 after buying an additional 17,283 shares during the period. 80.63% of the stock is owned by institutional investors.

A number of equities research analysts have issued reports on the stock. SunTrust Banks, Inc. reissued a “buy” rating and set a $96.00 target price on shares of Medtronic PLC in a research note on Monday. BidaskClub raised shares of Medtronic PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Jefferies Group LLC reissued a “buy” rating and set a $96.00 target price on shares of Medtronic PLC in a research note on Thursday, September 28th. Zacks Investment Research lowered shares of Medtronic PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, UBS AG reissued an “overweight” rating on shares of Medtronic PLC in a research note on Thursday, August 24th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. Medtronic PLC currently has a consensus rating of “Hold” and a consensus price target of $88.98.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/06/shufro-rose-co-llc-decreases-holdings-in-medtronic-plc-mdt.html.

Medtronic PLC (MDT) opened at 79.51 on Friday. The company has a market cap of $107.70 billion, a P/E ratio of 26.76 and a beta of 1.01. The stock’s 50 day moving average is $80.25 and its 200 day moving average is $83.34. Medtronic PLC has a 12-month low of $69.35 and a 12-month high of $89.72.

Medtronic PLC (NYSE:MDT) last posted its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. The company had revenue of $7.39 billion during the quarter, compared to analysts’ expectations of $7.44 billion. Medtronic PLC had a net margin of 13.75% and a return on equity of 12.92%. Medtronic PLC’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.03 EPS. On average, equities analysts forecast that Medtronic PLC will post $4.77 earnings per share for the current year.

Medtronic PLC declared that its board has approved a share repurchase program on Friday, June 23rd that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical technology company to repurchase up to 49% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 29th will be paid a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.31%. The ex-dividend date of this dividend is Thursday, September 28th. Medtronic PLC’s dividend payout ratio is presently 61.95%.

In other news, EVP Bryan C. Hanson sold 12,000 shares of the firm’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $88.57, for a total transaction of $1,062,840.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Omar Ishrak sold 140,407 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the sale, the chief executive officer now owns 668,503 shares of the company’s stock, valued at approximately $54,569,899.89. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.